Michael Wall1, Mark J Kupersmith2, Matthew J Thurtell3, Heather E Moss4, Elizabeth Ann Moss2, Peggy Auinger5. 1. Department of Neurology, University of Iowa, Iowa City, Iowa; Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, Iowa. Electronic address: michael-wall@uiowa.edu. 2. Mount Sinai West and New York Eye and Ear Infirmary, New York, New York. 3. Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, Iowa. 4. Illinois Eye and Ear Infirmary, Chicago, Illinois. 5. Center for Human Experimental Therapeutics, University of Rochester, Rochester, New York.
Abstract
PURPOSE: To determine whether the beneficial effects of acetazolamide (ACZ) in improving vision at 6 months continues to month 12 in participants of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). DESIGN: Nonrandomized clinical study. METHODS: In the IIHTT, subjects were randomly assigned to placebo-plus-diet or maximally tolerated dosage of acetazolamide-plus-diet. At 6 months subjects transitioned from study drug to ACZ. This resulted in the following groups: (1) ACZ to ACZ; n = 34; (2) placebo to ACZ; n = 35; (3) ACZ to no treatment; n = 16; and (4) placebo to no treatment; n = 11. Ninety-six IIHTT subjects had evaluations at 6 and 12 months. Our main outcome measure was change from month 6 to month 12 in visual fieldmean deviation (MD) with secondary measures being change in papilledema grade, ETDRS scores, and quality-of-life (QoL) measures. RESULTS: The ACZ to ACZ group improved 0.35 dB, P = .05; placebo subjects with no ACZ improved 0.81 dB MD, P = .07 at 12 months. The other groups improved 0.35-0.46 dB MD. Mean improvements in papilledema grade occurred most markedly in the group that exchanged placebo for ACZ (0.91 units, P < .001). QoL and headache disability scores showed significant improvements in the placebo group with added ACZ. CONCLUSION: Improvements in MD continued from month 6 to month 12 of the IIHTT in all treatment groups, most marked in the placebo group tapered off study drug. Adding ACZ to the placebo group significantly improved papilledema grade, headache, and QoL measures.
RCT Entities:
PURPOSE: To determine whether the beneficial effects of acetazolamide (ACZ) in improving vision at 6 months continues to month 12 in participants of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). DESIGN: Nonrandomized clinical study. METHODS: In the IIHTT, subjects were randomly assigned to placebo-plus-diet or maximally tolerated dosage of acetazolamide-plus-diet. At 6 months subjects transitioned from study drug to ACZ. This resulted in the following groups: (1) ACZ to ACZ; n = 34; (2) placebo to ACZ; n = 35; (3) ACZ to no treatment; n = 16; and (4) placebo to no treatment; n = 11. Ninety-six IIHTT subjects had evaluations at 6 and 12 months. Our main outcome measure was change from month 6 to month 12 in visual field mean deviation (MD) with secondary measures being change in papilledema grade, ETDRS scores, and quality-of-life (QoL) measures. RESULTS: The ACZ to ACZ group improved 0.35 dB, P = .05; placebo subjects with no ACZ improved 0.81 dB MD, P = .07 at 12 months. The other groups improved 0.35-0.46 dB MD. Mean improvements in papilledema grade occurred most markedly in the group that exchanged placebo for ACZ (0.91 units, P < .001). QoL and headache disability scores showed significant improvements in the placebo group with added ACZ. CONCLUSION: Improvements in MD continued from month 6 to month 12 of the IIHTT in all treatment groups, most marked in the placebo group tapered off study drug. Adding ACZ to the placebo group significantly improved papilledema grade, headache, and QoL measures.
Authors: Jorge C Kattah; John H Pula; Luis J Mejico; Michael P McDermott; Mark J Kupersmith; Michael Wall Journal: J Neurol Date: 2015-07-10 Impact factor: 4.849
Authors: Michael Wall; Michael P McDermott; Karl D Kieburtz; James J Corbett; Steven E Feldon; Deborah I Friedman; David M Katz; John L Keltner; Eleanor B Schron; Mark J Kupersmith Journal: JAMA Date: 2014 Apr 23-30 Impact factor: 56.272
Authors: Kathleen B Digre; Beau B Bruce; Michael P McDermott; Kristin M Galetta; Laura J Balcer; Michael Wall Journal: Neurology Date: 2015-05-20 Impact factor: 9.910
Authors: Brian A Raphael; Kristin M Galetta; Dina A Jacobs; Clyde E Markowitz; Grant T Liu; M Ligia Nano-Schiavi; Steven L Galetta; Maureen G Maguire; Carol M Mangione; Denise R Globe; Laura J Balcer Journal: Am J Ophthalmol Date: 2006-10-13 Impact factor: 5.258
Authors: M Kosinski; M S Bayliss; J B Bjorner; J E Ware; W H Garber; A Batenhorst; R Cady; C G H Dahlöf; A Dowson; S Tepper Journal: Qual Life Res Date: 2003-12 Impact factor: 4.147
Authors: Deborah I Friedman; Michael P McDermott; Karl Kieburtz; Mark Kupersmith; Ann Stoutenburg; John L Keltner; Steven E Feldon; Eleanor Schron; James J Corbett; Michael Wall Journal: J Neuroophthalmol Date: 2014-06 Impact factor: 3.042
Authors: Ivan J Suñer; Gregg T Kokame; Elaine Yu; James Ward; Chantal Dolan; Neil M Bressler Journal: Invest Ophthalmol Vis Sci Date: 2009-02-28 Impact factor: 4.799
Authors: Catherine R Sheils; William S Fischer; Rachel A Hollar; Lisa M Blanchard; Steven E Feldon Journal: Am J Ophthalmol Date: 2018-08-04 Impact factor: 5.258